Study context
- Study design
- Systematic review or meta-analysis
- Population or model
- Animal model; verify the species in the source
Research question
What does this source report about PT-141 -, and what evidence model and limitations apply?
Limitations
Confirm the complete study design, intervention identity, population or model, outcomes, statistical context, and limitations in the linked source before approval.
Original source
Pharmacologic therapeutic options for sexual dysfunction.
Claire S Burton, Kavita Mishra · Current opinion in obstetrics & gynecology · 2022
Source abstract
Sexual problems are reported by up to 45% of individuals assigned female at birth. Although sexual function is a complex biopsychosocial construct, there are a number of pharmacologic treatment options aimed at addressing the changing vaginal hormonal milieu in postmenopausal individuals and moderating the excitatory and inhibitory aspects of the central nervous system in those with hypoactive sexual desire disorder. The last decade has seen an increase in the number and type of pharmacologic treatment options for dysfunction primarily associated with menopause and hypoactive sexual desire disorder. Recent publications and systematic reviews have strengthened the safety data of existing FDA-approved medications as well as off-label therapies. Pharmacologic treatment with local estrogen and testosterone replacement in postmenopausal individuals and with centrally-acting therapies such as flibanserin, bremelanotide, and testosterone in premenopausal individuals assigned female at birth are safe and can be used to improve sexual desire and sexual satisfaction.
Related product
Review the complete product page, COAs, specifications, and all approved research sources.
PT-141 - 10mg research pageThis educational summary helps you review the cited source in context. The third-party article is not reproduced, and the citation does not imply endorsement of a related product.